挽救性放疗后长期尿控及影响因素:SAKK 09/10 剂量递增试验结果
SAKK 09/10 Ⅲ期随机试验分析 344 例前列腺癌挽救性放疗患者,比较常规 64 Gy 与剂量递增 70 Gy 对迟发性尿失禁的影响。中位随访 6.2 年,基线尿控者 47.2% 出现尿控下降,两组无显著差异(p=0.17);基线尿失禁者 54.1% 改善、16.2% 进一步恶化、29.7% 稳定,两组亦无差异(p=0.36)。神经保留技术与 24 个月时较少尿失禁相关,年龄和切除状态与 60 个月时尿失禁相关。
要点
- 剂量递增至 70 Gy 未显著增加迟发性尿失禁风险。
- 基线尿控者随访中近半数尿控下降,基线尿失禁者病程多变。
- 神经保留技术、年龄和切除状态与长期尿失禁相关。
核心结论
- 挽救性放疗后超过半数基线尿控患者随访期间维持尿控,尿失禁患者病程不一。
- 常规 64 Gy 与剂量递增 70 Gy 两组间迟发性尿失禁无显著差异。
研究设计与样本
- SAKK 09/10 为多中心随机对照 Ⅲ期试验,纳入接受挽救性放疗的前列腺癌患者。
- 患者随机接受常规 64 Gy 或剂量递增 70 Gy 挽救性放疗,共 344 例可评估患者。
主要发现
- 基线≥G1 尿失禁占 32.2%,≥G2 占 8.7%。
- 中位随访 6.2 年,基线尿控(<G1)患者中 47.2% 尿控下降(p<0.001),两组无显著差异(p=0.17)。
- 基线尿失禁患者中 54.1% 改善、16.2% 进一步恶化、29.7% 稳定,两组无显著差异(p=0.36)。
- 多因素 logistic 回归显示神经保留技术与 24 个月时较少尿失禁相关(p=0.029),年龄(p=0.031)和切除状态(p=0.046)与 60 个月时尿失禁相关。
- 放疗后 60 个月内泌尿症状持续加重,症状评分均值从基线 15.9 升至 60 个月时 22.9。
临床怎么用
- 剂量递增至 70 Gy 未显著增加迟发性尿失禁,支持其用于挽救性放疗。
- 应关注基线尿控者随访中尿控下降及基线尿失禁者的可变病程。
- 神经保留技术可能与 24 个月时较少尿失禁相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to investigate late urinary incontinence (UI) after salvage radiotherapy (sRT) and the effect of dose escalation on late UI, incontinence recovery, and quality of life (QoL) as part of the SAKK 09/10 phase III trial. METHODS: The SAKK 09/10 trial was a multicenter, randomized, controlled trial for prostate cancer patients receiving sRT. Eligible patients were randomized to receive either conventional (64 Gy) or dose-escalated (70 Gy) sRT. Baseline and follow-up data were collected on urinary incontinence related QoL, and treatment toxicity. RESULTS: 344 evaluable patients were analyzed. Baseline incontinence (≥Grade (G)1) was reported in 32.2 % of patients, with 8.7 % having ≥ G2. During follow-up (median 6.2 years), 47.2 % of the initially continent (<G1) patients showed a statistically significant (p < 0.001) decline in continence with no significant difference between the treatment groups (p = 0.17). Of the initially incontinent patients, 54.1 % showed an improvement whilst 16.2 % showed further decline. 29.7 % had stable UI. There was no significant difference between the treatment arms (p = 0.36). In multivariable logistic regression, nerve sparing technique was associated with less UI at 24 months (p = 0.029) and at 60 months age (p = 0.031) and resection status (p = 0.046) were significant. There was a steady worsening of urinary symptoms reported over 60 months post RT, with an increase in the symptom scales from a mean of 15.9 at baseline to 22.9 at 60 months. CONCLUSION: More than half of the patients that were continent at baseline remained continent during follow up while incontinent patients showed a variable course. UI was not different between the RT treatment arms.
引用
- Schröder C, Zwahlen DR, Schär S, et al. Long-term urinary continence and influencing factors after salvage radiotherapy: results of the SAKK 09/10 dose escalation trial. Radiother Oncol. 2025. PMID: 40639766. doi:10.1016/j.radonc.2025.111040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。